Want to see KLYG full AI Analyst Report?
Top Page
Kelyniam Global
(OTC:KLYG)
Select Model
Select Model
Rating:50Neutral
Price Target:
$0.12
▼(-5.38% Downside)
Action:Reiterated
Date:08/19/26
The score is held back primarily by weak and inconsistent cash flow and continued net losses despite strong TTM revenue growth and materially improved gross margins. Technicals are modestly supportive with price above key moving averages and neutral-to-positive momentum, while valuation remains constrained by a negative P/E and no dividend yield data.
Positive Factors
Strong TTM Revenue Growth
The sharp TTM revenue rebound indicates improving demand and renewed commercial traction. If sustained, stronger sales can provide operating leverage, support investment in the business, and create a larger base from which Kelyniam Global can pursue durable growth.
Negative Factors
Continued Net Losses
Persistent net losses show that improved revenue and gross margins have not yet translated into durable bottom-line profitability. Continued losses can weaken capital quality, limit internally funded expansion, and make future performance dependent on successfully controlling operating costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong TTM Revenue Growth
The sharp TTM revenue rebound indicates improving demand and renewed commercial traction. If sustained, stronger sales can provide operating leverage, support investment in the business, and create a larger base from which Kelyniam Global can pursue durable growth.
Read all positive factors
Kelyniam Global (KLYG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.17M
Dividend YieldN/A
Average Volume (3M)3.42K
Price to Earnings (P/E)―
Beta (1Y)0.06
Revenue Growth20.44%
EPS Growth82.13%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding50,123,430
10 Day Avg. Volume1,341
30 Day Avg. Volume3,417
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)7.17
Price to Sales (P/S)1.91
P/FCF Ratio-30.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kelyniam Global Business Overview & Revenue Model
Company Description
Kelyniam Global, Inc. operates as a medical device manufacturer, providing specialized solutions for patients. The company creates custom prosthetics using computer-aided design (CAD) and manufacturing (CAM) processes, employing advanced medical-g...
Kelyniam Global Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
57
Neutral
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.59M | 3.05M | 3.33M | 2.67M | 3.02M | 2.66M |
| Gross Profit | 2.78M | 2.30M | 1.63M | 2.04M | 2.20M | 2.04M |
| EBITDA | 151.94K | -59.16K | -996.00K | -197.69K | -7.06K | 274.49K |
| Net Income | -215.44K | -138.56K | -920.21K | -218.47K | -97.56K | 201.74K |
Balance Sheet | ||||||
| Total Assets | 1.68M | 1.75M | 1.77M | 1.63M | 1.71M | 1.43M |
| Cash, Cash Equivalents and Short-Term Investments | 96.94K | 104.51K | 153.08K | 9.07K | 0.00 | 0.00 |
| Total Debt | 384.42K | 508.82K | 418.39K | 631.99K | 559.88K | 308.10K |
| Total Liabilities | 990.84K | 938.68K | 884.26K | 1.01M | 945.32K | 738.08K |
| Stockholders Equity | 686.48K | 813.33K | 884.41K | 619.76K | 761.26K | 693.07K |
Cash Flow | ||||||
| Free Cash Flow | -31.33K | -193.86K | 97.02K | -95.77K | -83.46K | 113.66K |
| Operating Cash Flow | -31.33K | -193.86K | 103.58K | -95.77K | -31.75K | 124.30K |
| Investing Cash Flow | 0.00 | 0.00 | -5.41K | 0.00 | -51.70K | -10.64K |
| Financing Cash Flow | -29.70K | 145.28K | 45.85K | 104.84K | 83.46K | -113.66K |
Kelyniam Global Technical Analysis
Negative
0.13
Price Trends
0.14
Negative
0.13
Negative
0.13
Negative
Market Momentum
>-0.01
Positive
33.84
Neutral
-52.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KLYG, the sentiment is Negative. The current price of 0.13 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.14, and above the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 33.84 is Neutral, neither overbought nor oversold. The STOCH value of -52.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KLYG.
Kelyniam Global Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $6.17M | -27.91 | -29.31% | ― | 20.44% | 82.13% | |
47 Neutral | $2.85M | >-0.01 | -605.75% | ― | 8.36% | 88.88% | |
44 Neutral | $3.72M | -0.07 | -125.01% | ― | ― | 93.91% | |
43 Neutral | $3.98M | -0.03 | -129.76% | ― | 219.17% | 90.58% |
* Healthcare Sector Average
KLYG
Kelyniam Global
0.12
0.05
64.00%
NUWE
Nuwellis
0.78
-166.17
-99.53%
VTAK
Catheter Precision
0.21
-2.27
-91.53%
BBLG
Bone Biologics
0.57
-1.58
-73.58%
BJDX
Bluejay Diagnostics
0.83
-4.85
-85.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.